AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01494025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
Study NCT02868164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
Study NCT02868164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment
Study NCT02868164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Reduction
Description: routine exercise for weight reduction
Study NCT00271791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
Study NCT00271791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: PO, Placebo, 17 days
Study NCT01619488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Gastric Band
Description: Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction.
Study NCT00300612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Melanoma Vaccine
Description: Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
Study NCT01551108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: advanced behavioral strategies
Description: Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
Study NCT06105827 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control group
Description: Give antibiotics or diclofenac sodium suppository as needed.
Study NCT03424213 — intervention group
Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
Study NCT06105827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
Study NCT03383055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-MVA Triplex Vaccine
Description: * CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56
Study NCT04594668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senicapoc
Description: The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
Study NCT00952601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: Low carbohydrate diet
Study NCT03192514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Deprescribing tool
Description: Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions
Study NCT04843293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
Study NCT03623906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation colonoscopy
Description: Carbon dioxide insufflation colonoscopy
Study NCT03623906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation colonoscopy
Description: Room air insufflation colonoscopy
Study NCT04409496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support
Description: Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered.
Study NCT06105827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined group (Ningmitai plus tamsulosin)
Description: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
Study NCT01996683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desferal, ferriprox, blood transfusion
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation
Study NCT01996683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desferal, ferriprox, blood transfusion
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation
Study NCT04128280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TUDP
Description: a surgery: transurethral dilation of prostate with a columnar balloon
Study NCT03336671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus surgery
Description: Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
Study NCT03336671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy
Description: Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
Study NCT03336671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Description: Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
Study NCT01774604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 100 mg Indomethacin PR x 1
Study NCT01774604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04116671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromechanical Gait Assist
Description: A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
Study NCT02204878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
Study NCT03727529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill + VR
Description: Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
Study NCT04128280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TUIB
Description: a surgery: transurethral incision of bladder neck
Study NCT03727529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
Study NCT02616406 — intervention group
Intervention type: DEVICE
Intervention: GENEactiv
Description: To wear a monitoring device for a period of time prior to surgery and post surgery
Study NCT04409496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message support
Description: Subjects will receive regular SMS on generic smoking cessation for 3 months.
Study NCT04409496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help booklet
Description: Subjects will receive a standard self-help booklet on smoking relapse prevention.
Study NCT04409496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Description: Subjects will receive a standard self-help booklet on smoking relapse prevention.
Study NCT02043509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MiQuit
Description: MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
Study NCT03672552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFWP and Improved Oral Care
Description: The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
Study NCT03732157 — intervention group
Intervention type: PROCEDURE
Intervention: outpatient management of parathyroidectomy
Description: The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
Study NCT03732157 — intervention group
Intervention type: PROCEDURE
Intervention: conventional management of parathyroidectomy
Description: The patient stays overnight in hospital after intervention
Study NCT03665493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=1.5-2 Medications ON
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Study NCT03665493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=1.5-2 Medications OFF
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Study NCT03665493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy age-matched controls
Description: Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
Study NCT03665493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=3 Medications OFF
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Study NCT03665493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=3 Medications ON
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Study NCT01910779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 100 joule as first biphasic shock energy
Study NCT01910779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 120 joule as first biphasic shock energy
Study NCT04159935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux® system
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Study NCT03848637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug
Study NCT03848637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D387
Description: Reference drug
Study NCT00492895 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Discontinuation of Azathioprin
Description: Discontinuation of Azathioprin
Study NCT03850210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Splint
Description: Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
Study NCT03850210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Long Splint
Description: Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
Study NCT02094729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 2.5 mg/kg
Description: Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
Study NCT02094729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 5 mg/kg
Description: Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBT 986 CL, per i.v. infusion
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBT 986 CL, per i.v. infusion
Study NCT02259881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBT 986 CL, per i.v. infusion
Study NCT02094729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 10 mg/kg
Description: Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
Study NCT02094729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusions of placebo for 60 +/- 10 minutes.
Study NCT02283346 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy + hypofractionated EBRT
Description: Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints).
Study NCT04557995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erythropheresis
Description: Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
Study NCT01788111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low back exercises 1
Description: Excentric / concentric extension type exercises
Study NCT01788111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low back exercise 2
Description: Traditional low back training
Study NCT04359121 — intervention group
Intervention type: OTHER
Intervention: Questionnaires for specific phobia
Description: Questionnaires will be used.
Study NCT02683707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of Fentanyl from peri-procedural analgesia
Description: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Study NCT02683707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV peri-procedural analgesia
Study NCT02683707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local Anesthetic
Study NCT02683707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local Anesthetic
Study NCT02683707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV sedation
Study NCT02683707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: IV sedation
Study NCT02393222 — intervention group
Intervention type: OTHER
Intervention: Observing effect of routine HD
Description: Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
Study NCT00836303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorecatal Cancer Screening Activation
Description: Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
Study NCT04263415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
Study NCT04263415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-weekly injection with placebo pen for 16 weeks
Study NCT01955837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01955837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT05268068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion
Study NCT05268068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT03953989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
Description: Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment